Sevoflurane Vaporizer

Price 27-30 USD ($)/ Bottle

Get a Price/Quote

MOQ : 1000 Bottles

Sevoflurane Vaporizer Specification

Drug Type
Specific Drug

Physical Form
Liquid

Dosage
As Directed By Physician

Dosage Guidelines
As Directed By Physician

Storage Instructions
Store In a Cool & Dry Place

Sevoflurane Vaporizer Trade Information

Minimum Order Quantity
1000 Bottles

FOB Port
ALL INDIA

Payment Terms
Western Union, Paypal, Cash in Advance (CID), Cash Advance (CA)

Supply Ability
1000 Bottles Per Month

Delivery Time
2-3 Week

Sample Available
Yes

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Packaging Details
50 ml, 250 ml

Main Export Market(s)
Western Europe, Australia, North America, South America, Eastern Europe, Middle East, Central America, Asia, Africa

Main Domestic Market
All India

Certifications
WHO,GMP,COA As per client requirement

About Sevoflurane Vaporizer

Sevoflurane (1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane; synonym, fluoromethyl hexafluoroisopropyl ether), is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used as an inhalational anaesthetic for induction and maintenance of general anesthesia. After desflurane, it is the volatile anesthetic with the fastest onset and offset.

It is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, across all ages, as well as in veterinary medicine. Together with desflurane, sevoflurane is replacing isoflurane and halothane in modern anesthesiology. It is often administered in a mixture of nitrous oxide and oxygen.

Sevoflurane has an excellent safety record, but is under review for potential neurotoxicity, especially relevant to administration in infants and children, and rare reports similar to halothane hepatotoxicity. Sevoflurane is the preferred agent for mask induction due to its lesser irritation to mucous membranes.

Sevoflurane was discovered by Ross Terrel and independently by Bernard M Regan. A detailed report of its development and properties appeared in 1975 in a paper authored by Richard Wallin, Bernard Regan, Martha Napoli and Ivan Stern. It was introduced into clinical practice initially in Japan in 1990 by Maruishi Pharmaceutical Co., Ltd. Osaka, Japan. The rights for sevoflurane worldwide were held by AbbVie. It is now available as a generic drug.

Additional Information

The most widely recognized markets for this item incorporate the accompanying nations. you don't mind ask with us if your nation or district isn't recorded:

ASIA: Afghanistan, Israel, Jordan, Pakistan, Russia, Saudi Arabia, Singapore, Syria, Philippines, Turkey, Turkmenistan, Uzbekistan, Yemen, Vietnam, Indonesia, Malaysia, Iran, Tajikistan, and so forth.

AFRICA: South Africa, Uganda, Nigeria, Ghana, Kenya, Mauritius, Botswana, Egypt, Ethiopia, Libya, Sudan, Congo, Gambia, Ivory Coast , and so forth.

NORTH & SOUTH AMERICA: USA, Canada, Panama, Trinidad and Tobago, Costa Rica, Puerto Rico, Dominican Republic, Argentina, Guatemala, Guyana, Peru, Bolivia, Venezuela , Brazil, Bahamas, Ecuador, and so forth .

EUROPE: Austria , Azerbaijan, Belarus, Belgium, Cyprus, Czech Republic, Denmark, France, Georgia, Germany, Hungary, Ireland, Iceland, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Ukraine, United Kingdom (UK) , Latvia, and so forth.

OCEANIA: Australia, New Zealand, Fiji, and so forth.

Tell us about your requirement